Guy Travis Clifton

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

T. Conrads, G. Peoples, K. Darcy, 2016, Oncotarget.